Global Automotive Active Cornering System Market 2019-2023

自動車用アクティブコーナリングシステムの世界市場2019-2023

◆タイトル:Global Automotive Active Cornering System Market 2019-2023
◆商品コード:IRTNTR31354
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2019年5月21日
◆ページ数:127
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:米州、アジア、ヨーロッパ(EMEA)
◆産業分野:消費財
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥267,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥321,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥428,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

Technavio社の本調査レポートでは、自動車用アクティブコーナリングシステムの世界市場について調べ、自動車用アクティブコーナリングシステムの市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、自動車用アクティブコーナリングシステムの市場規模をセグメンテーション別(製品別(ダブラフェニブ、ソラフェニブ、ベムラフェニブ、エンコラフェニブ)、)と地域別(米州、アジア、ヨーロッパ(EMEA))に分けて算出しました。Technavio社は自動車用アクティブコーナリングシステムの世界市場規模が2019-2023期間中に年平均8%成長すると予測しています。
・サマリー
・レポートの範囲
・自動車用アクティブコーナリングシステムの市場状況
・自動車用アクティブコーナリングシステムの市場規模
・自動車用アクティブコーナリングシステムの市場予測
・自動車用アクティブコーナリングシステムの世界環境:ファイブフォース分析
・市場セグメンテーション:製品別(ダブラフェニブ、ソラフェニブ、ベムラフェニブ、エンコラフェニブ)
・自動車用アクティブコーナリングシステムの顧客状況
・主要地域別市場規模:米州、アジア、ヨーロッパ(EMEA)
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...

About this market

Prominent drugs based on BRAF kinase inhibitors, such as dabrafenib and sorafenib, are revolutionizing the therapeutic strategies of HCC, RCC, NSCLC, and melanomas. However, the high costs of these drugs remain a challenge to patients as well as the healthcare system. To overcome this challenge, many government and non-government organizations, including pharmaceutical companies, are focusing on providing financial assistance and clinical assistance for the treatment of various cancer indications. Effective patient assistance programs and reimbursement programs are expected to help with the high-cost regimen of BRAF kinase inhibitors to a large extent, which would encourage more patients to avail the treatment, thereby driving the market growth. Technavio’s analysts have predicted that the BRAF kinase inhibitors market will register a CAGR of over 8% by 2023.

Market Overview

Increasing prevalence of cancer

The prevalence of cancer has seen a significant rise in recent years globally, and the global pharmaceuticals market has witnessed the approval of various novel therapies, especially in the field of oncology. Hence, various companies are conducting heavy research on developing novel therapeutics, such as BRAF kinase inhibitors, to capture the huge unmet need, and the market has witnessed the approval of these drugs in the last two decades. Currently, BRAF kinase inhibitors are approved for some of the major cancers such as NSCLC, metastatic melanomas, and RCC. Therefore, the strong prevalence of various cancer indications is driving the growth of the global BRAF kinase inhibitors market.

Adverse effects of available drugs

BRAF kinase inhibitor therapeutics demonstrate a range of adverse effects such as fatigue, muscle cramps, nausea, vomiting, and diarrhea. The combination of BRAF kinase inhibitors and radiation therapy often leads to cytotoxic effects and myelosuppression. Despite being highly efficacious, the BRAF kinase inhibitors used for treating some of the oncology indications are associated with a spectrum of side effects. These side effects limit patient adherence to treatments, which poses a challenge to the market.

For the detailed list of factors that will drive and challenge the growth of the BRAF kinase inhibitors market during 2019-2023, view our report.

Competitive Landscape

The market appears to be moderately concentrated. The presence of few companies, including Array BioPharma Inc. and Bayer AG makes the competitive environment quite intense. Factors such as the improvements in production technology of BRAF kinase inhibitors and the growing demand for renewable energy and sustainable products will provide significant growth opportunities to the BRAF kinase inhibitor drug manufacturers. F. Hoffmann-La Roche Ltd., and Novartis AG. are some of the major companies covered in this report.

【資料の目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

Market segmentation by product

Comparison by product

Dabrafenib – Market size and forecast 2018-2023

Sorafenib – Market size and forecast 2018-2023

Vemurafenib – Market size and forecast 2018-2023

Encorafenib – Market size and forecast 2018-2023

Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 10: MARKET TRENDS

PART 11: VENDOR LANDSCAPE

Overview

Landscape disruption

Competitive scenario

PART 12: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Array BioPharma Inc.

Bayer AG

F. Hoffmann-La Roche Ltd.

Novartis AG

PART 13: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 14: EXPLORE TECHNAVIO

Exhibit 01: Global pharmaceuticals market

Exhibit 02: Segments of global pharmaceuticals market

Exhibit 03: Market characteristics

Exhibit 04: Market segments

Exhibit 05: Market definition – Inclusions and exclusions checklist

Exhibit 06: Market size 2018

Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 09: Five forces analysis 2018

Exhibit 10: Five forces analysis 2023

Exhibit 11: Bargaining power of buyers

Exhibit 12: Bargaining power of suppliers

Exhibit 13: Threat of new entrants

Exhibit 14: Threat of substitutes

Exhibit 15: Threat of rivalry

Exhibit 16: Market condition – Five forces 2018

Exhibit 17: Product – Market share 2018-2023 (%)

Exhibit 18: Comparison by product

Exhibit 19: Dabrafenib – Market size and forecast 2018-2023 ($ millions)

Exhibit 20: Dabrafenib – Year-over-year growth 2019-2023 (%)

Exhibit 21: Sorafenib – Market size and forecast 2018-2023 ($ millions)

Exhibit 22: Sales data of sorafenib

Exhibit 23: Sorafenib – Year-over-year growth 2019-2023 (%)

Exhibit 24: Vemurafenib – Market size and forecast 2018-2023 ($ millions)

Exhibit 25: Vemurafenib – Year-over-year growth 2019-2023 (%)

Exhibit 26: Encorafenib – Market size and forecast 2018-2023 ($ millions)

Exhibit 27: Encorafenib – Year-over-year growth 2019-2023 (%)

Exhibit 28: Market opportunity by product

Exhibit 29: Customer landscape

Exhibit 30: Market share by geography 2018-2023 (%)

Exhibit 31: Geographic comparison

Exhibit 32: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 33: North America – Year-over-year growth 2019-2023 (%)

Exhibit 34: Top 3 countries in North America

Exhibit 35: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 36: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 37: Top 3 countries in Europe

Exhibit 38: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 39: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 40: Top 3 countries in Asia

Exhibit 41: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 42: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 43: Top 3 countries in ROW

Exhibit 44: Key leading countries

Exhibit 45: Market opportunity

Exhibit 46: Patient assistance programs

Exhibit 47: New cases of cancer in the US 2015

Exhibit 48: Alternative therapies based on BRAF kinase inhibitors for various oncology indications

Exhibit 49: Side effects of BRAF kinase inhibitors

Exhibit 50: Impact of drivers and challenges

Exhibit 51: Approved drugs with respect to their cancer indications

Exhibit 52: Expansion of research areas of BRAF kinase inhibitors

Exhibit 53: Strategic alliances in global BRAF kinase inhibitors market

Exhibit 54: Vendor landscape

Exhibit 55: Landscape disruption

Exhibit 56: Vendors covered

Exhibit 57: Vendor classification

Exhibit 58: Market positioning of vendors

Exhibit 59: Array BioPharma Inc. – Vendor overview

Exhibit 60: Array BioPharma Inc. – Business segments

Exhibit 61: Array BioPharma Inc. – Organizational developments

Exhibit 62: Array BioPharma Inc. – Geographic focus

Exhibit 63: Array BioPharma Inc. – Key offerings

Exhibit 64: Array BioPharma Inc. – Key customers

Exhibit 65: Bayer AG – Vendor overview

Exhibit 66: Bayer AG – Business segments

Exhibit 67: Bayer AG – Organizational developments

Exhibit 68: Bayer AG – Geographic focus

Exhibit 69: Bayer AG – Segment focus

Exhibit 70: Bayer AG – Key offerings

Exhibit 71: Bayer AG – Key customers

Exhibit 72: F. Hoffmann-La Roche Ltd. – Vendor overview

Exhibit 73: F. Hoffmann-La Roche Ltd. – Business segments

Exhibit 74: F. Hoffmann-La Roche Ltd. – Organizational developments

Exhibit 75: F. Hoffmann-La Roche Ltd. – Geographic focus

Exhibit 76: F. Hoffmann-La Roche Ltd. – Segment focus

Exhibit 77: F. Hoffmann-La Roche Ltd. – Key offerings

Exhibit 78: F. Hoffmann-La Roche Ltd. – Key customers

Exhibit 79: Novartis AG – Vendor overview

Exhibit 80: Novartis AG – Business segments

Exhibit 81: Novartis AG – Organizational developments

Exhibit 82: Novartis AG – Geographic focus

Exhibit 83: Novartis AG – Segment focus

Exhibit 84: Novartis AG – Key offerings

Exhibit 85: Novartis AG – Key customers

Exhibit 86: Validation techniques employed for market sizing

Exhibit 87: Definition of market positioning of vendors



【掲載企業】

BorgWarner Inc.
Continental AG
Eaton
JTEKT Corp.
Robert Bosch GmbH
ZF Friedrichshafen AG

★調査レポート[自動車用アクティブコーナリングシステムの世界市場2019-2023] (Global Automotive Active Cornering System Market 2019-2023 / IRTNTR31354)販売に関する免責事項
[自動車用アクティブコーナリングシステムの世界市場2019-2023] (Global Automotive Active Cornering System Market 2019-2023 / IRTNTR31354)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆